How could the collaboration on new cancer therapies affect the FDA?
The collaboration on new cancer therapies could increase the FDA's regulatory review pipeline. The collaboration between Genmab and Incyte is focused on a Phase 1/2 study evaluating petosemtamab and INCB161734 for first-line treatment of metastatic colorectal cancer (mCRC) with a KRAS G12D mutation. As this study progresses and generates clinical data, the companies will submit findings and potential future applications to the FDA. This influx of novel investigational drug data and combination therapy proposals increases the volume and complexity of the regulatory submissions the FDA must review and assess.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within months
- The story
- Gone quiet
How it reaches FDA
-
Genmab and Incyte announced a clinical trial collaboration on October 24, 2026, to evaluate new cancer treatments. The Phase 1/2 study will test petosemtamab, an investigational antibody from Genmab, combined with INCB161734, an inhibitor from Incyte. The combination, along with standard-of-care chemotherapy, is being studied as a first-line treatment for patients with KRAS G12D-mutated metastatic colorectal cancer.
The full event1independent outlet -
As the Phase 1/2 study progresses, the resulting clinical data and the potential for a new first-line treatment approach will necessitate future regulatory submissions from Genmab and Incyte to the FDA for review and potential approval.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The collaboration will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC).manilatimes.net
- INCB161734 is an investigational, potent and selective KRAS G12D inhibitor.manilatimes.net
- KRAS mutations occur in approximately 40% of colorectal cancers, with G12D being the most common KRAS mutation.manilatimes.net
Why it matters
The FDA's role is critical in determining if novel cancer treatments can reach patients. An increase in the pipeline of investigational drugs, such as the combination of petosemtamab and INCB161734, means the agency must allocate resources to review complex, new mechanisms of action, like LGR5-targeted EGFR inhibition combined with KRAS G12D inhibition.
This collaboration is part of a broader trend in oncology research, where companies are exploring complementary scientific approaches to treat difficult-to-manage cancers. The FDA must balance the need to accelerate access to potentially life-saving treatments against the requirement for rigorous safety and efficacy data.
What we don't know yet
- What specific milestones or data points from the Phase 1/2 study will trigger the next regulatory submission?
- How will the FDA prioritize the review of this combination therapy against existing treatments for mCRC?
Is this still moving?
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- manilatimes.netOct 24
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.